Oncology Clinical Trial
Official title:
A Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients With Metastatic Solid Tumours and Haematologic Malignancies
This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable metastatic solid tumours and haematologic malignancies
This is a FIH Phase 1, non-comparative, open-label, basket-design study. The study will consist of 2 cohorts: - Solid tumours cohort - Haematologic malignancies cohort: Subjects must fulfill entry criteria and have relapsed or refractory advanced malignancy for which no standard therapy exists. An Data Safety Monitoring Committee (DSMB) will provide oversight of the study and will monitor safety on a regular basis throughout the study to make recommendations on any modifications. The study will be comprised of 3 periods. Screening, Treatment and Follow-up. All eligible subjects will receive minimally 3 weekly dosing of SUPLEXA. Subjects will be monitored closely at the clinic after each weekly infusion. After completion of the first 3 weekly SUPLEXA the treatment period of SUPLEXA may be extended to every 2 weeks until all SUPLEXA is depleted. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01439152 -
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
| Active, not recruiting |
NCT06015009 -
Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers
|
N/A | |
| Active, not recruiting |
NCT03298100 -
Risk Scoring Model for Endometrial Cancer
|
||
| Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04324320 -
Psychological Distress in Outpatient Oncological Rehabilitation
|
||
| Completed |
NCT00588289 -
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
|
N/A | |
| Recruiting |
NCT06222801 -
The 1st Tumor CytokinoTherapy Database (TCTD-1)
|
||
| Recruiting |
NCT03831633 -
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
|
Phase 4 | |
| Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
| Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
| Recruiting |
NCT05712174 -
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT03832062 -
Value of Analysing Under-utilised Leftover Tissue (VauLT)
|
||
| Completed |
NCT03988777 -
Magnetic Seed Localisation for Nonpalpable Breast Lesions
|
||
| Recruiting |
NCT06031233 -
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
|
Phase 4 | |
| Enrolling by invitation |
NCT04019119 -
Digital Intervention for the Modification of Lifestyles (iGame)
|
N/A | |
| Not yet recruiting |
NCT05926362 -
Capillary-Venous Paired Data Collection
|
||
| Recruiting |
NCT05686213 -
ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial
|
Phase 2 | |
| Recruiting |
NCT05510856 -
Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients
|
Phase 4 | |
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|